Hepatitis Vaccination in HIV Infection: Role of Adjuvant Interleukin-2 (HEPVACHIV)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00451984 |
Recruitment Status
: Unknown
Verified October 2007 by Aalborg Universitetshospital.
Recruitment status was: Recruiting
First Posted
: March 26, 2007
Last Update Posted
: November 1, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections Hepatitis A Hepatitis B | Biological: Twinrix Biological: interleukin-2 | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 80 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Study Start Date : | March 2007 |
- Antibody response to hepatitis A and hepatitis B

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adults with stable antiretroviral therapy and negative for hepatitis A or B
Exclusion Criteria:
- Prior hepatitis A or B

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00451984
Contact: Henrik Nielsen, MD, DMSci | +45-99326525 | henrik.nielsen@rn.dk |
Denmark | |
Department of Infectious Diseases, Aalborg Hospital | Recruiting |
Aalborg, Denmark, DK9000 | |
Principal Investigator: Raquel M Iguacel, MD | |
Sub-Investigator: Henrik Nielsen, MD, DMSci | |
Department of Infectious Diseases, Skejby Hospital | Not yet recruiting |
Aarhus, Denmark, DK8200 | |
Contact: Alex Laursen, MD, DMSci +45-89495566 | |
Principal Investigator: Ole Søgaard, MD |
Study Chair: | Henrik Nielsen, MD, DMSci | Aalborg Hospital, DK-9000 Aalborg, Denmark |
ClinicalTrials.gov Identifier: | NCT00451984 History of Changes |
Other Study ID Numbers: |
VN2005/32 |
First Posted: | March 26, 2007 Key Record Dates |
Last Update Posted: | November 1, 2007 |
Last Verified: | October 2007 |
Keywords provided by Aalborg Universitetshospital:
interleukin-2 vaccination treatment experienced |
Additional relevant MeSH terms:
Infection Hepatitis Hepatitis A HIV Infections Acquired Immunodeficiency Syndrome Hepatitis B Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Enterovirus Infections Picornaviridae Infections RNA Virus Infections Lentivirus Infections Retroviridae Infections |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Hepadnaviridae Infections DNA Virus Infections Interleukin-2 Antineoplastic Agents Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs |